Cayuga Biotech, a company that develops drugs that harness the body’s innate ability to heal and stop bleeding, presented preclinical data on its first generation, first-in-class, polyphosphate -based therapy designed to address life-threatening hemorrhage.
Novel therapy also shows low potential for off-target effects
NEW YORK--(BUSINESS WIRE)-- Cayuga Biotech, a company that develops drugs that harness the body’s innate ability to heal and stop bleeding, today presented preclinical data on its first generation, first-in-class, polyphosphate (polyP)-based therapy designed to address life-threatening hemorrhage. The results demonstrated that the polyP-SNP (silica nanoparticle) complex, in both standard and lethal triad conditions in vitro and ex vivo, generated thrombin 12 times faster than control, resulting in faster clotting with low potential for off-target thromboembolism. These data were presented in both oral and poster presentations at the Annual Meeting of the International Society for Thrombosis and Haemostasis in Bangkok, Thailand.
“The potential of exogenous polyP to stop noncompressible hemorrhage has previously been limited by its inability to be delivered systemically,” said study co-author James Morrissey, PhD, Professor of Biological Chemistry and Internal Medicine, Cardiology at the University of Michigan, who also led the characterization of polyphosphate’s hemostatic properties in humans. “These data are exciting because this novel polyP-SNP complex has overcome these limitations while demonstrating superior clotting in both standard and simulated ‘lethal triad’ (hemodilution, hypothermia and acidosis) conditions that compromise the body’s ability to stop bleeding.”
Data presented in the ISTH “New strategies for reversal and prevention of bleeding” session demonstrated faster clotting in vitro and ex vivo and acceleration of thrombin generation, which is the critical factor that determines the ability to clot quickly and effectively. As an injected drug that is inert in healthy tissue, the polyP-SNP complex travels via the bloodstream to any site of bleeding and acts to accelerate the clotting response without driving excess clotting. The activity of polyP-SNP complex is independent of FXII activation, which suggests a low potential for causing clotting in healthy tissue, a problem that has limited development for other injectable drugs to treat hemorrhage.
The study abstracts are available on the ISTH website at https://www.isth2024.org.
“A synthetic short-chain polyphosphate (polyP) complexed with silica nanoparticle (SNP), has pro-hemostatic activities as assessed by in vitro and ex vivo studies” (OC 43.2)
“A synthetic short-chain polyphosphate (polyP) complexed with silica nanoparticle (SNP), corrects coagulopathy under hemodilute, hypothermic, or acidotic conditions” (PB1047)
About Hemorrhage
Nearly 2 million people globally per year die of hemorrhage, the majority of which is preventable. The top causes of preventable death by hemorrhage are non-compressible hemorrhage sites (such as internal bleeding and from penetrating injury) and delays in hemostatic control neither of which are adequately addressed by today’s current care model. Due to the nature of non-compressible hemorrhage sites, the complexity of clinical intervention is time consuming and delays in treatment often lead to patient death.
About Cayuga Biotech, Inc.
Cayuga is developing novel biomimetic therapies leveraging inorganic polyphosphate, a polymer that modulates the healing response. The company has an optimized polyP-SNP complex in late preclinical development for the treatment of acute major hemorrhage, a discovery-stage novel composition for the treatment of inherited bleeding disorders, as well as a portfolio of early-stage programs focused across the healing continuum. To learn more, please visit www.CayugaBiotech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625026996/en/
Contacts
Andrea Ashford-Hicks
Media@cayugabiotech.com
Source: Cayuga Biotech, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20240625026996/en
